Discover 1 curated intelligence briefings related to this specific topic.
As of August 2026, the focus of metabolic health has shifted from treating diabetes to optimizing the healthy adult. With a market valuation hitting $18.85 billion, the rise of CGMs for non-diabetics and personalized hormone therapy is redefining resilience.
